Nanoparticle News and Research

RSS

In nanotechnology, a particle is defined as a small object that behaves as a whole unit in terms of its transport and properties. It is further classified according to size: in terms of diameter, fine particles cover a range between 100 and 2500 nanometers, while ultrafine particles, on the other hand, are sized between 1 and 100 nanometers.

Study shows delivering cancer drug in hydrophobic nanoparticle is a safe and effective prostate cancer therapy

Researchers at MIT and Brigham and Women's Hospital have shown that they can deliver the cancer drug cisplatin much more effectively and safely in a form that has been encapsulated in a nanoparticle targeted to prostate tumor cells and is activated once it reaches its target.

12 Jan 2011

Common disinfectant degrades water-borne viruses

A simple technique to make a common virus-killing material significantly more effective is a breakthrough from the Rice University labs of Andrew Barron and Qilin Li.

12 Jan 2011

IDEX enters definitive merger agreement to acquire Microfluidics International

IDEX Corporation today announced that it has entered into a definitive merger agreement to acquire Microfluidics International Corporation for $1.35 per share, net to the seller in cash, and subject to adjustment as provided in the merger agreement. The transaction is expected to close in the first quarter of 2011.

11 Jan 2011

Celator, Cephalon extend cancer research agreement

Celator Pharmaceuticals today announced that it has agreed with Cephalon, Inc. to extend an existing research agreement into the next phase of development. The research agreement provides for the utilization of Celator's proprietary technology in an ongoing drug development and life-cycle management program at Cephalon.

10 Jan 2011

BIND Biosciences commences BIND-014 Phase 1 clinical trial in cancer

BIND Biosciences announced today that it has initiated a Phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of BIND-014 in cancer patients. BIND-014, the first product candidate to enter clinical evaluation from BIND's broad proprietary Medicinal Nanoengineering platform, is a targeted polymeric nanoparticle containing the cytotoxic agent, docetaxel.

7 Jan 2011

Alnylam presents ALN-VSP Phase I trial results for liver cancer

Alnylam Pharmaceuticals, a leading RNAi therapeutics company, today presented new clinical data from its ALN-VSP Phase I liver cancer trial in a presentation at the Dana-Farber Cancer Institute in Boston. Results from molecular analysis of human biopsy samples showed achievement of pharmacologically relevant siRNA drug levels in tissues.

5 Jan 2011

Nanoparticles may help diagnose and treat pancreatic and ovarian cancer

The research - carried out by a group of five institutions, including Einstein, that comprise the Texas Center for Cancer Nanomedicine - could lead to novel ways to diagnose and treat pancreatic and ovarian cancer using nanoparticles.

4 Jan 2011

Researchers develop breath-analysis technology for rapid detection of biomarkers

Researchers have overcome a fundamental obstacle in developing breath-analysis technology to rapidly diagnose patients by detecting chemical compounds called "biomarkers" in a person's respiration in real time.

29 Dec 2010

Tekmira begins patient dosing in TKM-PLK1 phase 1 trail for cancer

Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference therapeutics, announced today it has initiated patient dosing in a Phase 1 human clinical trial for its lead oncology product, TKM-PLK1. TKM-PLK1 targets polo-like kinase 1, or PLK1, a cell cycle protein involved in tumor cell proliferation and a validated oncology target.

22 Dec 2010

New nanoparticle-based diagnostic platform provides rapid detection of sepsis

Blood poisoning can be fatal. If you suffer from sepsis, you used to have to wait as much as 48 hours for laboratory findings. A new diagnostic platform as big as a credit card will now supply the analysis after as little as an hour. This system is based on nanoparticles that are automatically guided by magnetic forces.

22 Dec 2010

Gold nanoparticles show great potential for tumour targeted drug delivery

The World Gold Council (WGC) is delighted with the successful phase 1 clinical trial of a unique nanomedicine that uses nanoparticles of gold as the core of a delivery system for tumour targeted drug delivery.

22 Dec 2010

Biomagnification of nanomaterials in simple food chain demonstrated

An interdisciplinary team of researchers at UC Santa Barbara has produced a groundbreaking study of how nanoparticles are able to biomagnify in a simple microbial food chain.

21 Dec 2010

Celator granted U.S. Patent covering CombiPlex technology platform

Celator Pharmaceuticals today announced the United States Patent and Trademark Office issued U.S Patent No. 7,850,990. This patent adds to the intellectual property surrounding Celator's innovative technology platforms and products.

17 Dec 2010

Alnylam Pharmaceuticals progress in delivery and translation of RNAi therapeutics

Alnylam Pharmaceuticals, a leading RNAi therapeutics company, presented new data at the 2010 International Chemical Congress of Pacific Basin Societies, being held in Honolulu, Hawaii, December 15-20.

17 Dec 2010

PEG-Prom encased nanoparticle aids in cancer detection and treatment

In a proof of principal study in mice, scientists at Johns Hopkins and the Virginia Commonwealth University have shown that a set of genetic instructions encased in a nanoparticle can be used as an "ignition switch" to rev up gene activity that aids cancer detection and treatment.

16 Dec 2010

Nanoparticles could combat Listeria

A Purdue University research team developed a nanoparticle that can hold and release an antimicrobial agent as needed for extending the shelf life of foods susceptible to Listeria monocytogenes.

8 Dec 2010

Positive data from Celator's CPX-351 Phase 2 study in newly-diagnosed AML presented at 52nd ASH

Celator Pharmaceuticals today announced positive clinical data in elderly patients with newly-diagnosed acute myeloid leukemia (AML) treated with CPX-351 (Cytarabine:Daunorubicin) Liposome Injection. Data were presented from the podium at the 52nd American Society of Hematology (ASH) Annual Meeting in Orlando, Florida.

8 Dec 2010

MU nanomedicine experts form new partnership with Shasun Pharmaceuticals

University of Missouri leaders celebrated a nanomedicine milestone today as they announced the creation of a new drug development company. The new company forms a partnership between university researchers and an international pharmaceutical firm to advance testing of a potential cancer treatment created at MU.

3 Dec 2010

Sirnaomics cemented partnership with Chinese pharmaceutical to develop siRNA therapeutics

Sirnaomics, Inc. announced today that the company has cemented a partnership with a Chinese pharmaceutical company for development of its small interfering RNA (siRNA) therapeutic (STP705) for scarless wound healing.

3 Dec 2010

Scientists discover a new method to produce gold nanoparticles

Gold nanoparticles, tiny pieces of gold so small that they can't be seen by the naked eye, are used in electronics, healthcare products and as pharmaceuticals to fight cancer. Despite their positive uses, the process to make the nanoparticles requires dangerous and extremely toxic chemicals. While the nanotechnology industry is expected to produce large quantities of nanoparticles in the near future, researchers have been worried about the environmental impact of the global nanotechnological revolution.

30 Nov 2010